Literature DB >> 27474257

Evaluation of a Proton Pump Inhibitor for Sleep Bruxism: A Randomized Clinical Trial.

H Ohmure1, K Kanematsu-Hashimoto1, K Nagayama1, H Taguchi2, A Ido2, K Tominaga3, T Arakawa3, S Miyawaki4.   

Abstract

Bruxism is a repetitive jaw-muscle activity characterized by clenching or grinding of the teeth and/or bracing or thrusting of the mandible. Recent advances have clarified the relationship between gastroesophageal reflux and sleep bruxism (SB). However, the influence of pharmacological elimination of gastric acid secretion on SB has not been confirmed. The authors aimed to assess the efficacy of a proton pump inhibitor (PPI) on SB and to examine the gastrointestinal (GI) symptoms and endoscopic findings of the upper GI tract in SB patients. The authors performed a randomized double-blind placebo-controlled crossover study at Kagoshima University Hospital. Twelve patients with polysomnography (PSG)-diagnosed SB underwent an assessment of GI symptoms using the frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) and esophagogastroduodenoscopy. At baseline (i.e., before interventions), the mean frequencies of electromyography (EMG) bursts and rhythmic masticatory muscle activity (RMMA) episodes were 65.4 ± 49.0 bursts/h and 7.0 ± 4.8 episodes/h, respectively, and at least 1 RMMA episode with grinding noise was confirmed in all participants. The mean FSSG score was 8.4 ± 5.6, and 41.7% of patients were diagnosed with gastroesophageal reflux disease. Mild reflux esophagitis was confirmed in 6 patients. PSG, including EMG of the left masseter muscle and audio-video recording, was performed on days 4 and 5 of administration of 10 mg of the PPI (rabeprazole) or placebo. PPI administration yielded a significant reduction in the frequency of EMG bursts, RMMA episodes, and grinding noise. No significant differences were observed regarding the swallowing events and sleep variables. Since the clinical application of PPI for SB treatment should remain on hold at present, the results of this trial highlight the potential application of pharmacological gastroesophageal reflux disease treatment for SB patients. Larger scale studies are warranted to corroborate these findings. (UMIN Clinical Trials Registry: UMIN000004577). © International & American Associations for Dental Research 2016.

Entities:  

Keywords:  crossover studies; deglutition; double-blind method; gastroesophageal reflux; placebos; randomized controlled trial

Mesh:

Substances:

Year:  2016        PMID: 27474257     DOI: 10.1177/0022034516662245

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  5 in total

1.  Associations among gastroesophageal reflux disease, mental disorders, sleep and chronic temporomandibular disorder: a case-control study.

Authors:  Yuanyuan Li; Ming Fang; Lina Niu; Yu Fan; Yan Liu; Yong Long; Xiaodong Liu; Franklin R Tay; Jihua Chen
Journal:  CMAJ       Date:  2019-08-19       Impact factor: 8.262

2.  The dental demolition derby: bruxism and its impact - part 2: early management of bruxism.

Authors:  Mark L T Thayer; Rahat Ali
Journal:  Br Dent J       Date:  2022-05-27       Impact factor: 2.727

3.  Associations among Bruxism, Gastroesophageal Reflux Disease, and Tooth Wear.

Authors:  Yuanyuan Li; Fan Yu; Lina Niu; Wei Hu; Yong Long; Franklin R Tay; Jihua Chen
Journal:  J Clin Med       Date:  2018-11-06       Impact factor: 4.241

Review 4.  Managements of sleep bruxism in adult: A systematic review.

Authors:  Hajime Minakuchi; Masanori Fujisawa; Yuka Abe; Takashi Iida; Kyosuke Oki; Kazuo Okura; Norimasa Tanabe; Akira Nishiyama
Journal:  Jpn Dent Sci Rev       Date:  2022-03-25

Review 5.  Gut Bless Your Pain-Roles of the Gut Microbiota, Sleep, and Melatonin in Chronic Orofacial Pain and Depression.

Authors:  Łukasz Lassmann; Matteo Pollis; Agata Żółtowska; Daniele Manfredini
Journal:  Biomedicines       Date:  2022-06-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.